

































Infantile hypertrophic pyloric stenosis in monozygotic
twins: a case report and review of genetic and
modifiable risk factors
Dustin Bakera, Michael A. Finkelc, Kelsey A. Finkeld and Robert Mordenb
Infantile hypertrophic pyloric stenosis is the most common
surgical pathology resulting in emesis presenting in infancy
and is usually encountered between the second and eighth
weeks of life. It is the most common indication for surgery
in infants less than 1 month of age. Prior to the
pyloromyotomy developed by Ramstedt in 1911, the
mortality for the condition exceeded 50%. Current
epidemiologic data indicate that the ailment affects
between two and five infants per 1000 live births. Despite
the incidence of the condition, the etiologic factors, genetic
or environmental, have yet to be clearly elucidated. The
incidence in twins has been previously described and noted
to be nearly 200 times higher in monozygotic twins. The
incidence in dizygotic twins is similar to that between
siblings, but nearly 30 and 20 times higher than that of the
general population, respectively. This observation continues
to stress the importance of genetics in the development of
pyloric hypertrophy. Presented here are two cases of
idiopathic infantile hypertrophic pyloric stenosis in
monozygotic twins with a review of the literature of both
genetic and environmental predisposing factors. Ann
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Introduction
Infantile hypertrophic pyloric stenosis occurs with an
incidence in the Western world of two to five per 1000
live births. The onset of symptoms is usually abrupt and
dramatic, presenting with nonbilious emesis resulting from
hypertrophy and hyperplasia of the pylorus. This hyper-
trophy causes a functional gastric outlet obstruction,
usually between the second and eighth week of life [1].
Prior to recognition of the disease as an entity by
Hirschsprung in 1888 [2] followed by the first pyloromyot-
omy performed by Ramsteatd in 1911 [3], mortality rates
exceeded 50% [4]. Although our current understanding of
the diagnosis and management of the ailment has resulted
in excellent results with present day mortality rates being
close to 0%, the exact etiology remains enigmatic. The
skewed sex distribution, familial clustering, and high
concordance in twins that have been demonstrated by
multiple studies suggest a genetic cause, but without
following any mode of Mendelian inheritance. Current
models of inheritance that have been proposed include the
multifactorial threshold model and the single major locus
model, the latter of which proposed environmental
modification of a single gene [5,6]. Presented here are
cases of pyloric stenosis in monozygotic male twins and a
review of the current understanding of the pathogenesis
and genetic and environmental factors that have been
implicated in the process. Prior reports of twins with
pyloric stenosis in the literature have largely been limited
to isolated case reports [7–19].
Case report
Both twins were born at 30 weeks and 2 days gestation to a
28-year-old G1P0 nonsmoking nonobese Caucasian
mother via spontaneous vaginal delivery secondary to
preterm premature rupture of membranes. The twins were
dichorionic, diamniotic, and both were males. Zygosity
testing was completed postnatally, demonstrating the
probability of monozygosity of 366 503 427 739 : 1.
The mother received steroids and magnesium in the late
preterm period. The pregnancy was otherwise unremark-
able. Twin A was born measuring 43 cm long and weighing
1.7 kg with APGAR scores of 8 and 9 at 1 and 5min. Twin
B was born 5min after twin A, measured 42 cm and
weighed 1.681 kg with APGAR scores of 7 and 8. Both
twins spent a total of 4 weeks in the neonatal ICU for
hyaline membrane disease, hyperbilirubinemia, and apnea
of prematurity before being discharged home at 34 weeks
and 1 day of gestation. Total parenteral nutrition was
provided to both twins through 36 h of life, when
nasogastric feeding tubes were placed. Nasogastric tubes
were permanently removed at 24 days of life in twin A and
26 days of life in twin B. Of note, twin A had his
nasogastric tube placed to a depth of 18 cm after 36 h of
life, and underwent insertion of the nasogastric apparatus a
total of five times before discharge from the neonatal ICU.
Twin B had his nasogastric tube placed to a depth of 18 cm
after 36 h of life, and underwent insertion of the
nasogastric apparatus twice prior to discharge from the
neonatal ICU. Both infants were fed exclusively breast-
milk through the nasogastric tube, with breastfeeding and
bottle-feeding occurring during daytime ad lib until
nasogastric tubes were removed. After this period, both
twins were exclusively fed breastmilk by bottle.
Both infants were placed in a supine position when
sleeping. No prenatal exposure to thalidomide, hydan-
toins, or trimethadione, or postnatal exposure to ery-
thromycin was present. Family history is significant for
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classic phenylketonuria (PKU) in the father. Both twins
received negative newborn screening results for PKU.
No known familial history of pyloric stenosis was noted
in the immediate or extended family.
Twin A presented at 33 days of life with a short history of
nonbilious projectile emesis and intolerance to feeds.
Abdominal examination and electrolytes at presentation
were unremarkable. An ultrasound was obtained (Fig. 1)
which demonstrated a pyloric wall of 6 mm in thickness
and measured at least 2 cm long with an antral nipple
sign. An open Fredet-Ramstedt pyloromyotomy was
performed on the day of presentation and was without
complication. Postoperatively, the patient suffered a
transient emesis and intolerance to feeds. This resolved
after 12 h, at which time feeds were advanced. The
remainder of the hospital course was unremarkable and
discharge was achieved on postoperative day 2.
Twin B presented at 44 days of life with a history of
nonbilious nonprojectile emesis for 4 days followed by
1 day of projectile emesis. Abdominal examination and
electrolytes at presentation was unremarkable. Ultra-
sound imaging demonstrated a pyloric wall measuring
5 mm in thickness and was at least 2 cm in length
(Fig. 1). An open Fredet-Ramstedt pyloromyotomy was
performed and was complicated by a small mucosal
perforation on the duodenal side of the myotomy. The
perforation was repaired primarily with polydioxanone
suture. The remainder of the procedure was unremark-
able. Postoperatively, initiation of feeds was delayed by
12 h, given the mucosal repair. Feeds were started,
advanced, and tolerated without issue, and the infant was
discharged home on postoperative day 1.
At follow-up at 9 months of age, both twins continue
to tolerate advancements in feeding and demonstrate
satisfactory weight gain and achievement of develop-
mental milestones.
Discussion
The etiology of pyloric stenosis remains enigmatic
despite an excellent understanding of the diagnosis and
management of infants with this pathology. An interac-
tion between environmental factors and a genetic
predisposition likely explains the complex inheritance.
The general consensus is that no single gene model,
regardless of penetrance, is responsible for the observed
patterns of inheritance [5,20]. The first feature that
suggested a genetic influence is the male predominance.
Multiple epidemiological studies demonstrated a male :
female ratio of 4–5 : 1 across multiple countries [1]. The
incidence is highest in white non-Hispanic infants and
lowest in Asians, the latter occurring at a quarter of the
rate of non-Hispanic white infants [1,21]. In addition to
male predominance, birth order was noted as early as
1927 to be associated with pyloric stenosis. Although
multiple studies have looked at birth order, they have
not demonstrated a first-born predominance, but rather a
decreasing risk with increasing birth order with an odds
ratio (OR) for first born of approximately two and
decreasing to close to one by the fourth birth [1,22].
Additional evidence of a possible genetic influence comes
from the association with multiple syndromes and
malformations. Associated anomalies including diaphrag-
matic hernias, esophageal atresia, and urinary malforma-
tions have been reported in association with pyloric
Fig. 1
Abdominal ultrasound. Twin A at 33 days of life (left) measuring 6 mm in thickness and 2 cm in length with antral nipple sign (arrow) representing
protruding pyloric mucosa. Twin B at 44 days of life (right) measuring 5 mm in thickness over 2 cm in length.
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stenosis [23], as well as syndromes including trisomy 21,
trisomy 18, Denys-Drash, Smith–Lemli–Opitz (defect in
cholesterol metabolism), Cornelia de Lange (dysfunctional
Notch signaling pathway), nephrotic syndrome type I,
PKU, congenital lipodystrophy type IV, FG syndrome,
familial visceral neuropathy, Costello (H-Ras mutation),
Alpert, Opitz, Marden–Walker, X-linked ichthyosis, dupli-
cations 1q, 9q, deletion 11q, and fetal alcohol syndrome
[21,24].
Genetic analyses have localized multiple candidate genes
that may predispose to the development of pyloric stenosis
(Table 1). The most thoroughly investigated of these has
been the gene for neuronal nitric oxide synthetase (nNOS,
NOS1, IHPS1, 12q24). Both gene expression at the mRNA
level and protein expression are reduced or dysfunctional in
some infants with pyloric stenosis [25,26]. It has been
postulated that nitric oxide, an inhibitory neurotransmitter
in the gastrointestinal tract that acts via guanylyl cyclase and
generation of cGMP, is decreased. This results in
pylorospasm, a prolonged inappropriate contraction that
result in pyloric muscular hypertrophy, particularly of the
circular layer [18,26,27]. Histologic analysis demonstrated
distorted and enlarged enteric nerve fibers which also
demonstrated reduced nNOS expression [26,28]. Genome-
wide linkage analyses demonstrated multiple novel sites, as
well as a linkage to locus 12q24, the site of the NOS1 gene
[29,30]. However, others demonstrated that while variants of
the gene are present in some pyloric stenosis patients, they
did not demonstrate an increased association with pyloric
stenosis [31]. Although a promising candidate gene,
immunohistologic analysis demonstrated reduced or absent
expression of nitric oxide synthetase in only a minority of
patients with pyloric stenosis [32]. Tetrahydrobiopterin, a
cofactor for the phenylalanine hydroxylase enzyme, is also a
cofactor for neuronal nitric oxide synthase [33,34]. Given the
infants’ paternal history of classic PKU and the autosomal
recessive inheritance, the infants can be assumed to be
heterozygous carriers of the phenylalanine hydroxylase
enzyme deficiency.
Other candidate genes, some X-linked, include those
coding for transient receptor potential cation channels that
are expressed on smooth muscle cells. These membrane
channels are thought to be mechanosensitive, possibly
responding to luminal boluses in the region, eventually
leading to smooth muscle hypertrophy [21,30,33]. Recent
molecular research has demonstrated a lack of c-Kit
expression and cells of Cajal in the pylorus [34,35],
suggesting a dysfunction of myenteric innervation of
smooth muscle may be an important factor in the
pathogenesis [36]. This is further supported by the
decreased expression of heme oxygenase-2, which pro-
duces carbon monoxide that functions in signal transduc-
tion between cells of Cajal and pyloric smooth muscle cells
[37]. Other candidate genes identified with linkage
analysis but of uncertain significance include glucagon-
like peptide-2, motilin, neuropeptide Y [29], and those
related to cholesterol metabolism [38]. The infants in this
case study presented 11 days apart with pyloric stenosis,
with twin A having had triple the number of insertions of
nasogastric feeding tubes compared with twin B prior to
the diagnosis of this condition, bringing into question
whether stimulation of the pylorus with either a foreign
body or luminal bolus can result in transient receptor
potential cation channel activation, possibly relating to
pathophysiology of pyloric hypertrophy.
Familial aggregation studies have demonstrated a clear
increased incidence of pyloric stenosis in Denmark,
suggesting a strong genetic influence. Rate ratios were
evaluated for monozygotic and dizygotic twins, siblings,
half-siblings, cousins, and half cousins, which were 182,
29.4, 18.5, 5, 3, and 1.6, respectively, clearly demonstrat-
ing that the more genetic information shared, the greater
the chance of concordance [11]. The relatively minor
difference in the risk between siblings and dizygotic
twins suggests that the influence of the in-utero
environment is likely minor. The influence of parents
with a history of pyloric stenosis on the offspring
demonstrates an increased risk, but it was much more
pronounced if the mother is affected, with increased risk
ratio of 10 for an affected father, and 40 for an affected
mother [39]. No direct family history of pyloric stenosis is
described in this case.
Prenatal and postnatal exposure to a variety of drugs is
associated with an increased incidence, the most notable
being erythromycin. Concerns for a causal relationship
between postnatal erythromycin exposure and the
development of pyloric stenosis developed after two
clusters of disease developed after postnatal exposure
[40,41]. Motilin induces gastric contractions, is the target
for erythromycin in the gastrointestinal tract, and has
Table 1 Candidate genetic factors in the pathophysiology of infantile hypertrophic pyloric stenosis
Gene/protein/cofactor Normal function Proposed mechanism of influencing pathogenesis
Neuronal nitric oxide synthase Generates nitric oxide→activates guanylyl cyclase→smooth
muscle relaxation
Reduced generation of inhibitory neurotransmitter increasing
smooth muscle tone leading to hypertrophy
Transient receptor potential
cation channels
Smooth muscle mechanoreceptors Stimulation increases calcium inflow into smooth muscle increasing
tone and leading to potential hypertrophy
Heme oxygenase-2 Produces carbon monoxide used in signal transduction Dysfunctional communication between interstitial cells of Cajal and
pyloric smooth muscle cells
Glucagon-like peptide-2 Trophic factor for intestinal epithelium, inhibitory of apoptosis,
role in motility
Possible role in pyloric hypertrophy
Neuropeptide Y Inhibitory enteric neurotransmitter Involved in smooth muscle relaxation
Phenylalanine hydroxylase Rate-limiting enzyme in the degradation of phenylalanine to
tyrosine. Association in linkage analysis
Shares common cofactor, tetrahydrobiopterin, with nitric oxide
synthase
Motilin Role in initiating myoelectric motility complex. Association in
linkage analysis
Erythromycin, a motilin agonist, associated with disease
development
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been the center of investigation for a drug-induced
etiology for pyloric stenosis. However, no association
between the gene sequence variants of motilin and
pyloric stenosis has been demonstrated [42]. Metanalysis
involving nine studies, two of which were randomized
control trials, demonstrated an OR with any erythromy-
cin exposure of 2.45, but increased to 10.5–12.89 when
looking at infants exposed in the first 14 days of life
[43,44]. In addition, prenatal exposure to hydantoins,
trimethadione, and thalidomide increased the incidence
of pyloric stenosis [45]. Prostaglandin therapy for infants
with a patent ductus arteriosus was suggested as a
possible risk factor [46]. Maternal tobacco smoking has
been explored and demonstrated an ORs of 1.82–2.1 in
multiple epidemiologic analyses [47,48]. The twins
presented here were unexposed to these substances
prenatally and postnatally.
A number of environmental factors have been implicated
as etiologic factors in the pathogenesis. A case–control
study in Sweden examining the factors related to
pregnancy and in-utero exposure determined that pre-
maturity (OR: 2.54), cesarean delivery (OR: 1.67), and
maternal age less than 20 years (OR: 1.42) are associated
with an increased incidence of pyloric stenosis. In addition,
birth order 2 or more (OR: 0.78) was associated with a
decreased risk [47]. Maternal breastfeeding is protective
[49,50]. The infants here were both premature, born
vaginally at 30 weeks and 2 days gestation, and were
exclusively fed breastmilk, yet presented 11 days apart.
Studies from Denmark and Sweden, where there has been
the largest decline in the incidence of pyloric stenosis noted
in the literature, have demonstrated a parallel decrease in
the rate of sudden infant death syndrome (SIDS) after a
countrywide recommendation that all infants be placed in a
supine sleeping position to prevent SIDS [51–53]. Radi-
ologic evidence demonstrated that feeds preferentially
accumulate in the fundus and proximal stomach when the
infant was supine, but in the antrum and pylorus when
prone [52]. These findings have the potential to both offer a
mechanical cause to explain the parallel decline in SIDS
and pyloric stenosis, as well as provide a simple, highly
effective means of disease prevention. The infants de-
scribed here were bottle-fed in the right lateral decubitus
position prior to their diagnosis.
Gastric hyperacidity has been implicated as another possible
etiologic factor in the pathogenesis of pyloric stenosis.
Infants display elevated gastrin levels through the fourth
week of life which, coupled with immature epithelium, can
lead to mucosal thickening. This latter finding is proposed
as the primary alteration leading to pyloric stenosis
secondary to chronic contractions in response to hyperacid-
ity [54]. Others have suggested an inherited higher parietal
cell mass as being a possible factor [55]. Studies evaluating
Heliobacter pylori infection in infants as a factor failed to show
any association [36,56,57].
Conclusion
Despite the excellent current knowledge of disease
diagnosis and management, the etiological factors leading
to the development of pyloric stenosis remain elusive. The
exact mechanism is likely polygenetic susceptibility that is
influenced by postnatal environmental factors. Given the
high concordance and familial aggregation, strong consid-
eration should be given to ultrasound screening of infants
that are siblings or twins of an infant diagnosed with pyloric
stenosis.
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